Shenzhen Bay Laboratory has synthesized G protein-coupled receptor GPR139 agonists reported to be useful for the treatment of Parkinson’s disease, epilepsy, pain, depression, schizophrenia, substance abuse and dependence, post-traumatic stress and autism spectrum disorders.
Neuroninn Biosciences Co. Ltd. has disclosed G protein-coupled receptor GPR139 agonists reported to be useful for the treatment of anxiety, depression, Parkinson’s disease and more.
Neuroninn Biosciences Co. Ltd. has synthesized G protein-coupled receptor GPR139 agonists reported to be useful for the treatment of anxiety disorders, depression, substance abuse and dependence and Parkinson’s disease.
GPR139 is an orphan G protein-coupled receptor expressed in neurons of the mediobasal hypothalamus that has been proposed as a target for disorders such as Parkinson’s disease, alcohol addiction or schizophrenia, among others.
Shanghaitech University has identified G protein-coupled receptor GPR139 agonists reported to be useful for the treatment of schizophrenia, among others.
